Norditropin Original 30 IU Novo Nordisk

 

Information for those wishing to buy Norditropin Original 30 IU in the UK

Norditropin Original 30 IU from Novo Nordisk is an artificial growth hormone originally intended for medical use only. But, as is often the case, over time this pharmacological agent has been used by athletes in the UK. The growth hormone was developed for the treatment of children with stunted growth, so its composition is as safe as possible for the body. The substance has gained popularity among sportsmen. It can be used for increasing overall body endurance, increasing training intensity and building muscle mass.

Advantages of using Norditropin Original 30 IU from Novo Nordisk

The product has a strong effect that stimulates cell and bone growth. The metabolic processes are considerably accelerated during the course of the product, which is of special importance for sportsmen from England. The formula contains synthetic somatropin, which helps restore the content of natural somatotropin. As a result, in athletes:

• increases muscle mass;
• gets rid of fatty tissue;
• gets a great feeling of well-being and additional strength.

Using Norditropin Original 30 IU growth hormone makes the body’s bone tissue rebuild, which makes the skeleton more powerful and able to withstand the high loads a bodybuilder has to face. Weight loss starts at first, which is due to the resorption process, and then there is a steady weight gain afterwards. The appropriate dosage can only be determined individually, which depends on the condition of the body and how it tolerates the components of the drug.

Packaging video review Norditropin Original 30 IU Novo Nordisk

 

 

 

 

 

Effects of Norditropin Original 30 IU from Novo Nordisk

The main effects of Norditropin Original 30 IU include stimulation of skeletal and muscle growth and a significant effect on metabolic processes.

The treatment of growth hormone deficiency leads to normalization of body proportions, increase of muscle mass and decrease of fat mass.

Most of the somatropin´s effects are mediated through insulin-like growth factor I (IGF-I), IGF-I, which is produced in many body tissues, but mainly in the liver. More than 90% of IGF-I forms complexes with binding proteins (IGFBP), among which IGFBP-3 plays the most important role.

Lipolytic and protein-preserving effects of the growth hormone are important under stress. Somatropin also increases the intensity of metabolic processes in the bones, as indicated by the increased concentration of bone tissue markers in plasma. In adult patients, the bone mass decreases slightly during the first months of treatment due to a more pronounced resorption, but it increases after long-term treatment.

Contraindications for Norditropin Original 30 IU from Novo Nordisk

Any suspicion of an actively growing malignancy. Before starting treatment with growth hormone Norditropin Original 30 IU, it must be assured that the intracranial tumour is inactive and that anti-tumour therapy has been completed.

Severe patients with complications of open-chest or abdominal heart surgery, multiple trauma, acute respiratory failure or similar conditions should not be treated. During pregnancy and breast-feeding. Hypersensitivity to any component of the drug. In children with chronic kidney disease, treatment with Norditropin should be discontinued before kidney transplantation.

Special safety precautions.

Only clear, colourless Norditropin Original 30 IU can be used. If you have had to press the button more than 6 times before the first injection to remove the air from the syringe pen, you must not use this preparation.

Children treated with Norditropin Original 30 IU should be regularly examined by a child growth disorder specialist. Treatment with the product should be prescribed by a doctor specialising in the treatment of insufficient growth hormone secretion. This also applies to the treatment of Turner syndrome and chronic kidney diseases as well as intrauterine growth retardation in children.

The drug is not administered as a growth stimulant in children with closed growth zones of the epiphyses of the tubular bones.

Before starting growth hormone treatment in children with chronic kidney disease, the presence of growth abnormalities must be accurately established with optimal renal therapy by observation for one year. Conservative treatment of uremia with conventional drugs should be continued during the period of use of the drug and dialysis should be used if necessary.

In patients with chronic renal disease, renal function is usually reduced. As a precautionary measure, renal function should be monitored continuously during treatment with Norditropin NordiLet in order not to miss an excessive decrease or increase in glomerular filtration rate (risk of hyperfiltration).

A small number of patients with growth hormone deficiency, some of whom have been treated with somatropin, have had leukaemia. However, it is unlikely that this is due to somatropin administration.

In patients with complete remission of benign or malignant tumors, an increase in recurrence rate is not associated with growth hormone treatment. However, patients who have achieved complete remission of a malignant growth should be kept under close surveillance in order not to miss a possible relapse after starting growth hormone therapy.

Slipped epiphysis of the femoral head often occurs in patients with endocrine diseases, and Legg-Calve-Perthes disease often develops in people with short stature. These diseases cause claudication or pain in the hip or knee joints. Doctors and relatives should be aware of this.

In case of severe or recurrent headache, visual disturbances, nausea and/or vomiting, it is advisable to perform an ophthalmoscopy to check for optic nerve swelling. If this is confirmed, a mild form of intracranial hypertension could be suspected. In this case, growth hormone treatment should be discontinued.

To date, the management of patients whose attacks of intracranial hypertension have ceased has not been definitively resolved. When resuming treatment with growth hormone, the possibility of the onset of symptoms should be monitored carefully.

Norditropin Original 30 IU in adults with growth hormone deficiency should preferably be treated under the care of an endocrinologist specialising in the treatment of pituitary gland pathology.

Adult growth hormone deficiency is a lifelong condition that requires appropriate treatment. However, experience in treating patients over 60 years of age and adults with a treatment duration longer than 5 years is still limited.

Ability to drive vehicles and operate potentially dangerous machinery. No effect.

Overdose

Acute overdose initially leads to hypoglycaemia, subsequently to hyperglycaemia. Hypoglycaemia can only be detected by biochemical analysis (i.e. no clinical symptoms). An overdose of the drug over a long period of time leads to the development of symptoms arising from excessive production of growth hormone in the body.